Boston Scientific скачать в хорошем качестве

Boston Scientific

Let’s explore #Boston #Scientific—a $128 billion medical tech giant that's delivering both innovation and solid financials! Valued at $136 billion, #BostonScientific has a forward P/E of 32, suggesting strong growth expectations, though a #peg of 2.1 shows this isn’t #bargain territory. Profitability looks solid with a 12% profit margin, an ROA of 4.8%, and an ROE of 9%, demonstrating effective asset and equity management. With $15 billion in revenue and $1.8 billion in net income, the company clearly plays in the big leagues of medical devices. Their balance sheet shows $2.9 billion in cash and a manageable 53% debt-to-equity ratio, providing flexibility for growth. Levered free cash flow is a healthy $1.6 billion, giving them the financial muscle for ongoing innovation. If you’d invested $1,000 five years ago, you’d see it double to around $2,000 today. And a daily $1 investment over five years? You’d be looking at about $2,700, thanks to compounding. In summary, Boston Scientific combines strong profitability, manageable debt, and steady growth potential, making it a solid choice for investors in medical tech.